Recent Updates
Recently added Catalysts

XOMA Royalty Corporation

XOMAFDA catalysts, PDUFA dates & pipeline intelligence
$40.17
▲ 0 · 0%

Last traded Jul 13, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full XOMA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $22.2952W HIGH $42.81
Volume
6.71 M
Value Traded
271.40 M
Short % Float
7.51%
Days to Cover
5.0
-0.45%Week
+4.46%1 Month
+70.35%3 Month
+31.35%6 Month
+68.69%1 Year
+31.6%5 Year
-99.18%All Time

Cash Data

Unlock XOMA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
522.33 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
12.39 M
Float Shares
12.19 M
Insiders
0.29%
Institutions
42.16%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every XOMA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

XOMA Catalyst Timeline

Dated clinical, regulatory and corporate events for XOMA Royalty Corporation

Catalyst Timeline

Dated clinical, regulatory & corporate events for XOMA Royalty Corporation

242Total events
3Upcoming
81Tier-1 (high impact)
2012 to 2027Coverage

Upcoming catalysts 2

T2R&D Day
Subscribe to view catalyst details
T2Quarterly Update
Subscribe to view catalyst details

Event history 50

▲AcquiredCorporate
Ligand completes acquisition of XOMA Royalty
◆AcquisitionCorporate
Ligand to acquire XOMA Royalty for $39.00 per share in cash
●Quarterly UpdateCorporate
Quarterly preferred stock dividend declared
◆AcquiredCorporate
XOMA to be acquired by Ligand Pharmaceuticals for $739 million
◆AcquisitionCorporate
Pending merger with Ligand Pharmaceuticals
▲Quarterly UpdateCorporate
Ligand increases 2026 adjusted EPS guidance to $8.50-$9.50
●Oral PresentationPresentation
Ligand investor call to discuss acquisition
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results and business update webcast
◆Oral PresentationPresentation
Leerink 2026 Global Healthcare Conference
◆Oral PresentationPresentation
T.D. Cowen 46th Annual Health Care Conference
Unlock the full XOMA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How XOMA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-12-31Seralutinib Phase 3 data readout Phase 3
Unlock 2 more XOMA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
0
Drugs Scored
rNPV / MCap
Top Drug
Showing 0 of 12 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Unlock the XOMA pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every XOMA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every XOMA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock XOMA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Montano Maricel PereaOfficer (Chief Legal Officer)Other -42,306 $0.00 07/14/2026
Unlock the full XOMA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
BVF INC/IL 8.3 % (219.2 %) 322.72 M 7.59 M 193.14% ( 5.00 M)
Unlock every fund holding XOMA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in XOMA
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see XOMA ownership
Insider and institutional ownership, quarter by quarter.

XOMA Short Interest

Shares sold short, counted twice a month.

7.51%
Short % of Float
of tradable shares sold short
914.9K
Shares Sold Short
+1.8% vs prior count
5.0 High
Days to Cover
trading days of normal volume to buy every short share back
181.5K
Avg Daily Volume
the average used for days to cover
Unlock XOMA short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock XOMA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live XOMA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock XOMA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How XOMA ranks across every disease it competes in

Competitive Position is a premium feature
See how XOMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

XOMA News

About XOMA Royalty Corporation

Emeryville, CA 14 employees xoma.com
Headquarters2200 POWELL STREET, EMERYVILLE, CA, 94608
BIOPHARMAWATCH ELITE
Trade the next XOMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime